Search Results
Sep 10, 2026, 10:30 ET Hylenr Technologies encuentra indicios de tierras raras
instituciones de investigación internacionales.Parte de este trabajo, titulado 'Firmas nucleares en un sistema de confinamiento reticular de Ni-Pd cargado con hidrógeno', se presentó a principios de este mes en la 27ª Conferencia Internacional sobre Ciencia Nuclear de la Materia Condensada
More news about: HYLENR
Sep 10, 2026, 02:21 ET Hylenr Technologies 發現稀土元素特徵訊號，藉核聚變開闢全新技術路徑
這些發現是 Hylenr Technologies 過去十多年基於晶格約束核聚變技術的研究成果之一。公司亦與國際領先科研機構合作，對相關研究成果進行驗證。部分研究成果以《Nuclear Signatures in a Hydrogen-Loaded Ni–Pd Lattice Confinement System》為題，於本月較早時在加拿大尼亞加拉瀑布城舉行的第 27 屆國際凝聚態核科學大會（ICCF-27）上發表。從核能到核合成核合成是透過原子核轉變，形成不同
More news about: HYLENR
Sep 10, 2026, 00:24 ET Hylenr Technologies、希土類元素のシグナルを確認、核融合で新たな技術への道を開く
Technologiesが過去10年以上にわたり取り組んできた、格子閉じ込め核融合という方式に基づく核融合技術研究の一環です。同社は主要な国際研究機関とも協力し、検証を行ってきました。この研究の一部である「Nuclear Signatures in a Hydrogen-Loaded Ni–Pd Lattice Confinement System」は、今月初め、第27回凝縮系核科学国際会議（27th International Conference on Condensed Matter Nuclear Science、ICCF-27）が開催されたカナダ・ナ
More news about: HYLENR
Sep 09, 2026, 23:55 ET 하이레나 테크놀로지스, 희토류 시그니처 발견…핵융합을 통한 새로운 기술 경로 열어
핵융합(Lattice Confinement Fusion)을 기반으로 진행해 온 핵융합 기술 연구의 일환이며, 주요 국제 연구기관들과의 협업과 검증도 진행됐다.이 연구의 일부인 '수소 충전 Ni–Pd 격자 구속 시스템에서의 핵반응 시그니처(Nuclear Signatures in a Hydrogen-Loaded Ni–Pd Lattice Confinement System)'은 이달 초 캐나다 나이아가라 폭포에서 열린 제27회 응집물질 핵과학 국제회의(27th International Conference
More news about: HYLENR
Sep 09, 2026, 16:31 ET Hylenr Technologies entdeckt Spuren von Seltenen Erden und eröffnet durch Kernfusion einen neuen technologischen Weg
führenden internationalen Forschungseinrichtungen validiert.Ein Teil dieser Arbeit mit dem Titel Nuclear Signatures in a Hydrogen-Loaded Ni–Pd Lattice Confinement System wurde Anfang dieses Monats auf der 27th International Conference on Condensed Matter Nuclear Science (ICCF-27)
More news about: HYLENR
Sep 09, 2026, 16:23 ET Hylenr Technologies détecte des traces de terres rares et ouvre une nouvelle voie technologique grâce à la fusion nucléaire
plan.Une partie de ces travaux, intitulée « Nuclear Signatures in a Hydrogen-Loaded Ni–Pd Lattice Confinement System » (Signatures nucléaires dans un système de confinement par réseau Ni-Pd chargé en hydrogène), a été présentée au début du mois lors de la 27e Conférence internationale
More news about: HYLENR
Sep 09, 2026, 11:02 ET Two Independent Research Teams Converge on Novel Immune Checkpoint PLA2G2D as a Path to Overcome Anti-PD-1 Resistance in Cancer
Nature publication indicate that PD-1 and PLA2G2D are nonredundant and reciprocally regulated. More importantly, blockade of PLA2G2D not only restores anti-tumor immunity in preclinical models resistant to anti-PD-1 therapy but also potentiates the activity of anti-PD-1 in tumor types that are otherwise
More news about: Apeximmune
Sep 09, 2026, 10:28 ET ImmunoGenesis Announces Appointment of Reza Mazhari and Mike Davis to Its Board of Directors
immuno-oncology by targeting key mechanisms of immune resistance. The company's lead product, IMGS-001, is a cytotoxic immune checkpoint inhibitor targeting PD-L1 and PD-L2. IMGS-001 is currently in a phase 1a/b clinical trial for the treatment of immune-excluded tumors, which account for more than half of all cancers.
More news about: Immunogenesis Inc.
Sep 09, 2026, 07:30 ET Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially
More news about: Kazia Therapeutics Limited
Sep 09, 2026, 07:12 ET Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy
the advancement of the program globally.In a Phase 2 clinical study conducted by Harbour BioMed, porustobart in combination with tislelizumab, a PD-1 inhibitor, demonstrated a 30% objective response rate (7 of 23 patients) in late-line patients with MSS metastatic colorectal cancer without liver
More news about: Harbour BioMed
Sep 09, 2026, 07:00 ET Marengo Therapeutics Completes Enrollment in Phase 1/2 STARt-001 Monotherapy Cohorts and Strengthens Leadership to Advance Invikafusp Alfa Toward Late-Stage Development
monotherapy cohorts represents an important step in establishing invikafusp alfa's single-agent activity across eight distinct PD-1–resistant tumor types, including MSS colorectal cancer, PD-L1–negative non-small cell lung cancer and triple-negative breast cancer," said Zhen Su, M.D., MBA, President and Chief
More news about: Marengo Therapeutics
Sep 09, 2026, 06:45 ET Canada Nickel Announces Filing of NI 43-101 Technical Reports for Previously Announced Updated Deloro Project Resource and Initial Nesbitt Project Resource
43-101 Mineral Resource Estimate and Technical Report for the Deloro Ni-Co-Pd-Pt Deposit, Deloro Nickel Sulphide Project", and "National Instrument 43-101 Initial Mineral Resource Estimate and Technical Report for the Nesbitt Ni-Co-Pd-Pt Deposit, Nesbitt Nickel Sulphide Project" The Reports were prepared
More news about: Canada Nickel Company Inc.
Sep 09, 2026, 06:20 ET Hylenr Technologies descubre firmas de tierras raras y abre una nueva vía tecnológica a través de la fusión nuclear
primer orden.Una parte de este trabajo, titulada «Nuclear Signatures in a Hydrogen-Loaded Ni–Pd Lattice Confinement System» (Firmas nucleares en un sistema de confinamiento reticular Ni-Pd cargado de hidrógeno), se presentó a principios de este mes en la 27.ª Conferencia Internacional
More news about: HYLENR
Sep 09, 2026, 06:05 ET A Hylenr Technologies identifica assinaturas de elementos de terras raras e abre um novo caminho tecnológico para a fusão nuclear
instituições de pesquisa internacionais.Uma parte deste trabalho, intitulado "Assinaturas Nucleares em um Sistema de Confinamento em Rede Ni–Pd Carregado com Hidrogênio", foi apresentada no início deste mês na 27ª Conferência Internacional sobre Ciência Nuclear da Matéria Condensada (ICCF-27) em
More news about: HYLENR
Sep 09, 2026, 03:18 ET Hylenr Technologies Finds Rare-Earth Signatures, Opens New Technology Pathway Through Nuclear Fusion
collaborated and validated with leading international research institutions.A part of this work, titled 'Nuclear Signatures in a Hydrogen-Loaded Ni–Pd Lattice Confinement System,' was presented earlier this month at the 27th International Conference on Condensed Matter Nuclear Science (ICCF-27) at
More news about: HYLENR
Sep 09, 2026, 03:12 ET Hylenr Technologies Finds Rare-Earth Signatures, Opens New Technology Pathway Through Nuclear Fusion
collaborated and validated with leading international research institutions.A part of this work, titled 'Nuclear Signatures in a Hydrogen-Loaded Ni–Pd Lattice Confinement System,' was presented earlier this month at the 27th International Conference on Condensed Matter Nuclear Science (ICCF-27) at
More news about: HYLENR
Sep 08, 2026, 13:39 ET Pexar, Powered by Lexar, Launches PexarBolt Ultra TBT5 Dock with a 5-Inch Visual Dashboard
compatible laptops, desktops, and workstations to displays, storage, networking, and peripherals. The Thunderbolt 5 host port supports up to 140W USB PD 3.1 charging for compatible laptops, while two front USB-C ports share up to 45W for charging phones, tablets, and other accessories."We're in
More news about: Pexar
Sep 08, 2026, 09:00 ET IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
combination regimens. Building on the DeLLphi-303 trial, which showed very encouraging efficacy and tolerability results for IMDELLTRA in combination with anti-PD-L1 checkpoint inhibitors in the treatment of first-line ES-SCLC, DeLLphi-305 was designed to evaluate IMDELLTRA earlier in the course of disease, where
More news about: Amgen
Sep 08, 2026, 07:30 ET Quantinuum finaliza financiamento de US$ 100 milhões para P&D no âmbito da Lei CHIPS com o Departamento de Comércio dos EUA para avançar na fabricação de computadores quânticos de íons aprisionados nos Estados Unidos
multimedia:https://www.prnewswire.com/br/comunicados-para-a-imprensa/quantinuum-finaliza-financiamento-de-us-100-milhoes-para-pd-no-ambito-da-lei-chips-com-o-departamento-de-comercio-dos-eua-para-avancar-na-fabricacao-de-computadores-quanticos-de-ions-aprisionados-nos-estados-unidos-302871720.htmlFONTE
More news about: Quantinuum
Sep 08, 2026, 07:30 ET Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control arm) in first-line patients with treatment-naïve, PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC). Baseline prognostic factors were largely balanced
More news about: Inhibrx Biosciences, Inc.
Sep 08, 2026, 07:00 ET Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
adaptive platform trial as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902, Compugen's anti-TIGIT antibody, is being developed by AstraZeneca pursuant
More news about: Compugen Ltd.
Sep 08, 2026, 03:00 ET Power Metallic Defines High-Grade Maiden Resource at Lion Averaging ~3.9% CuEq, with >85% Indicated and Significant Expansion Potential
for expansion.Lion contains 4,145,000 Mt Indicated at 3.86% CuEq (1.68% Cu, 2.61 g/t Pd, 0.85 g/t Pt, 0.49 g/t Au, 12.21 g/t Ag, 0.10% Ni), and 601,000 Mt Inferred at 4.01% CuEq (1.84% Cu, 2.86 g/t Pd, 0.59 g/t Pt, 0.41 g/t Au, 12.47 g/t Ag, 0.13% Ni).Locked-cycle testing completed by SGS
More news about: Power Metallic Mines Inc.
Sep 04, 2026, 16:00 ET Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control arm) in first-line patients with treatment-naïve, PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).
More news about: Inhibrx Biosciences, Inc.
Sep 04, 2026, 10:00 ET Come Talk To ME, Featuring AI-Recreated Voice, Selected for Twin Cities Film Fest
Come Talk To ME follows Parkinson's disease (PD) activist Jackie Hunt Christensen, her husband Paul Christensen, their two sons, and a diverse group of friends with PD. Their stories reflect on the many types of communication that are necessary to participate
More news about: COME TALK TO ME LLC
Sep 04, 2026, 00:13 ET TECNO Showcased New MEGABOOK Laptops and New Phones at IFA ShowStoppers 2026
is available on selected configurations, providing additional room for storage expansion. For mobile use, a 70Wh battery is paired with a compact 65W PD GaN charger, supporting longer periods of use.Beyond power, the series also delivers flexibility in connectivity. Support for up to Wi-Fi 6E and
More news about: TECNO